Validate Mitochondria-Lysosome Contact Site Dysfunction in PD

📖 Wiki Page

experiment2341 wordssynced 2026-04-02

Validate Mitochondria-Lysosome Contact Site Dysfunction in PD

Hypothesis

[GBA](/genes/gba) (glucocerebrosidase) mutations cause glucosylceramide accumulation in lysosomes, which disrupts mitochondria-lysosome contact site (MCS) formation and function, leading to impaired mitophagy and [alpha-synuclein](/proteins/alpha-synuclein) aggregation — a core pathogenic mechanism in GBA-associated Parkinson's disease. [VPS13D](/genes/vps13d), as a MCS-resident protein, is a therapeutic target whose modulators could restore MCS function and reduce neurodegeneration[@krainc2020].

Gap Addressed

While the [MLCS mechanism page](/mechanisms/mitochondria-lysosome-contact-sites) documents the structural and functional basis of MCS in neurodegeneration[@wong2018], and individual gene pages ([VPS13D](/genes/vps13d), [GBA](/genes/gba), [RAB7A](/genes/rab7a)) cover molecular players[@chao2022;@du2022], no experiment systematically tests the causal chain from GBA mutation to MCS dysfunction to pRab10 dysregulation to alpha-synuclein pathology in patient-derived neurons with VPS13D modulator rescue.

Experimental Design

Overall Strategy

Use isogenic iPSC-derived dopaminergic neurons from GBA N370S/+ carrier and CRISPR-corrected sibling lines. Apply quantitative TIRF microscopy to measure MCS frequency and dynamics[@lee2020], paired with biochemical assays for glucosylceramide accumulation, pRab10 signaling, and alpha-synuclein aggregation. Test VPS13D activators and protein stabilizers for rescue[@ma2023;@esser2022].

Model System

...

Validate Mitochondria-Lysosome Contact Site Dysfunction in PD

Hypothesis

Gap Addressed

Experimental Design

Overall Strategy

Model System

Cell Lines:

GBA-N370S/+ iPSC-derived dopaminergic neurons: Patient-derived (heterozygous carrier) — primary disease model
Isogenic CRISPR-corrected sibling lines: GBA-N370S/N370S isogenic rescue control
Age-matched healthy controls: Wild-type iPSC-derived dopaminergic neurons
VPS13D knockout line: CRISPR VPS13D knockout in GBA-N370S/+ background as MCS-dependence control

Differentiation: Dual Smads inhibition followed by floor plate induction → NKX2.1+ → FOXA2+ → TH+ dopaminergic neurons (60-day differentiation protocol). Confirm with flow cytometry and patch clamp.

Experimental Groups

| Group | Genotype | Treatment | Purpose |
|-------|----------|-----------|---------|
| 1 | GBA WT/WT | Vehicle | Healthy baseline |
| 2 | GBA N370S/+ | Vehicle | Patient disease model |
| 3 | GBA N370S/N370S | Vehicle | Homozygous Gaucher model |
| 4 | GBA N370S/+ | VPS13D activator | Therapeutic rescue |
| 5 | GBA N370S/+ | VPS13D protein stabilizer | Therapeutic rescue |
| 6 | GBA N370S/+ | Glucosylceramide synthase inhibitor (GZ/SAR402671) | Substrate reduction control |
| 7 | GBA N370S/+ VPS13D KO | Vehicle | MCS-dependence control |

Aim 1: Quantify MCS Frequency via TIRF Microscopy

Rationale

Total Internal Reflection Fluorescence (TIRF) microscopy selectively illuminates the basal ~100–200 nm of the cell, making it ideal for visualizing organelle contact sites at the plasma membrane-adjacent cytoplasm. When combined with mitochondrial (MitoTracker) and lysosomal (Lysotracker or CD63-mNeon) markers, TIRF enables high signal-to-noise quantification of MCS[@lee2020].

Protocol

Day 1: Neuron Seeding and Culture

Differentiate iPSCs to dopaminergic neurons (60-day protocol). Plate neurons on poly-L-ornithine/laminin-coated TIRF-quality glass-bottom dishes (World Precision Instruments) at 50,000 cells/cm².

Culture neurons in BrainPhys-based medium with BDNF, GDNF, db-cAMP, and ascorbic acid. Maintain for 14 days post-plating to allow process extension.

Confirm neuronal identity: >70% TH+ by immunocytochemistry, spontaneous firing by multi-electrode array.

Day 2: Labeling

Stain mitochondria: Add MitoTracker Green FM (100 nM, Thermo Fisher) for 30 min at 37°C. Wash 3× with Hanks' Balanced Salt Solution (HBSS).

Stain lysosomes: Add Lysotracker Deep Red (75 nM, Thermo Fisher) for 15 min at 37°C. Wash 3× with HBSS.

Alternative for fixed endpoint: Stain with anti-Tom20 (mitochondria, 1:200, Santa Cruz) and anti-CD63 (lysosomes, 1:100, BD Biosciences), followed by secondary antibodies (Alexa Fluor 488 and 647).

Day 3: TIRF Imaging

Use a TIRF microscope (Nikon Eclipse Ti2 or similar) with 100× oil-immersion objective (NA 1.49) and 488 nm / 640 nm laser lines.

Acquire 15–20 fields per dish, with 3–5 z-stacks (200 nm step) per field for colocalization confirmation.

Capture raw TIRF images at 100 ms exposure, gain 1, at 2048×2048 pixel resolution.

Image analysis (ImageJ/FIJI):

Segment mitochondria using Otsu thresholding on MitoTracker channel
Segment lysosomes using local maxima detection on Lysotracker channel
Identify MCS: pixels where both signals overlap within 30 nm (approximate MCS zone)
Quantify: (MCS pixel count / total mitochondrial pixels) × 100 for % mitochondrial contact area

Key Controls

Positive control: CCCP (10 μM, 2 h) — causes mitochondrial fragmentation and alters MCS dynamics. Expected: increased transient MCS frequency with fragmented mitochondria.
Negative control: Bafilomycin A1 (100 nM, 4 h) — inhibits v-ATPase, alkalinizes lysosomes, disrupts MCS. Expected: reduced MCS frequency.

Readouts

Primary: MCS frequency (% mitochondrial surface in contact with lysosome)
Secondary: MCS length (μm), MCS duration (seconds via live imaging), lysosome proximity index
n = 3 independent differentiations × 10 fields = 30 fields per condition

Aim 2: Measure Glucosylceramide and Lipid Species

Rationale

Glucosylceramide (GlcCer) accumulation is the direct biochemical consequence of GBA loss-of-function. GlcCer alters lysosomal membrane physical properties, disrupting MCS formation. Quantifying GlcCer establishes the primary biochemical defect[@lin2022].

Protocol

Lipid Extraction (Folch Method)

Harvest neurons (2 × 10⁶ cells per condition) in ice-cold methanol.

Add chloroform (2:1 ratio), sonicate 3 × 30 s on ice.

Separate phases by centrifugation (1,000 × g, 5 min). Collect lower (chloroform) phase containing GlcCer.

Dry under nitrogen gas. Resuspend in chloroform/methanol 1:1.

LC-MS/MS Quantification

Separate lipids on C18 column (Waters ACQUITY) with gradient: 80% methanol → 100% methanol over 15 min.

Detect GlcCer (d18:1/C16:0, C18:0, C24:0 species) using multiple reaction monitoring (MRM) on a triple quadrupole MS (Sciex QTRAP 6500+).

Normalize to total protein (BCA assay) and to internal standard (C12:0 GlcCer, Avanti Polar Lipids).

Lipid Panel

| Lipid | Species | Method |
|-------|---------|--------|
| Glucosylceramide | C16:0, C18:0, C24:0, C24:1 | LC-MS/MS MRM |
| Ceramide | C16:0, C18:0, C24:0 | LC-MS/MS MRM |
| Sphingomyelin | C16:0, C18:0 | LC-MS/MS MRM |
| Phosphatidylserine | Total | LC-MS/MS |
| Cardiolipin | Total | LC-MS/MS |

Aim 3: Measure pRab10 as MCS Activity Readout

Rationale

Rab10 is a key MCS-regulatory GTPase that localizes to lysosomes and regulates contact site formation[@du2022]. In PD models, phosphorylated Rab10 (pRab10, T73) is elevated due to LRRK2 kinase hyperactivity. pRab10 levels at lysosomes serve as a readout of MCS regulatory signaling.

Protocol

Western Blot

Lyse neurons in RIPA buffer with protease/phosphatase inhibitors.

Load 20 μg protein per lane on 4–12% Bis-Tris SDS-PAGE.

Transfer to PVDF membrane (0.45 μm).

Primary antibodies:

Anti-phospho-Rab10 (Thr73, 1:500, Thermo Fisher #701085)
Anti-total Rab10 (1:1,000, Cell Signaling #8127)
Anti-β-actin (1:5,000, Sigma) as loading control

5. Secondary: HRP-conjugated anti-rabbit IgG (1:10,000).

Develop with ECL substrate (SuperSignal West Pico). Image on ChemiDoc.

Quantify pRab10/total Rab10 ratio by densitometry (ImageLab).

Immunocytochemistry for pRab10 Localization

Fix neurons (4% PFA, 15 min), permeabilize (0.1% Triton X-100), block (5% BSA).

Stain with anti-pRab10 (Thr73) and anti-LAMP1 (lysosomal marker, 1:200, DHSB).

Image on confocal (Leica SP8) with 63× objective.

Quantify pRab10+ puncta colocalized with LAMP1+ lysosomes using ImageJ Pearson correlation.

Aim 4: Measure Alpha-Synuclein Aggregation

Rationale

[Alpha-synuclein](/proteins/alpha-synuclein) misfolding and aggregation is the hallmark of PD[@krainc2020]. MCS dysfunction impairs mitophagy[@wang2022], leading to accumulation of damaged mitochondria and reactive oxygen species that promote alpha-synuclein aggregation. Measuring pSer129 alpha-synuclein (pathological form) links MCS dysfunction to synucleinopathy[@lin2022].

Protocol

pSer129 Alpha-Synuclein ELISA

Lyse neurons in TBS buffer with 1% Triton X-100, protease/phosphatase inhibitors.

Measure total protein (BCA).

Load 100 μg total protein per well on alpha-synuclein ELISA kit (Signet/Covance, or Meso Scale Discovery).

Primary detection: anti-pSer129 (81A, 1:1,000) and anti-total alpha-synuclein (syn211, 1:1,000).

Read on plate reader (405 nm for TMB substrate or MESO Quick Plex).

Seed Amplification Assay (SAA)

Seed iPSC-derived neurons with 10% brain homogenate from GBA-PD patients or age-matched controls (0.1 μg total protein).

Culture for 14 days. Harvest neurons.

Perform RT-QuIC (real-time quaking-induced conversion) on cell lysate:

Mix 10 μL neuron lysate with 90 μL RT-QuIC buffer (40 mM phosphate buffer pH 8.0, 300 mM NaCl, 10 μM ThT)
Cycle: 42°C 30 s / 60°C 30 s, repeat 120 h
Monitor ThT fluorescence every 15 min

4. Report as ThT amplification half-time (hours to reach 50% max fluorescence).

Immunocytochemistry

Fix and stain neurons with anti-pSer129 alpha-synuclein (1:500, Abcam #51253) and anti-TH (1:200, Pel-Freez).

Quantify pSer129+ puncta per TH+ neuron using high-content imaging (ArrayScan or IN Cell Analyzer).

Aim 5: Test VPS13D Modulators

Rationale

[VPS13D](/genes/vps13d) is a core component of the MCS machinery[@chao2022;@velayosbaeza2020]. Small molecule activators and protein stabilizers may restore MCS function in GBA mutant neurons, providing a therapeutic proof-of-concept[@ma2023;@esser2022].

Modulator Compounds

| Compound | Mechanism | Source |
|----------|-----------|--------|
| VPS13D-A1 (experimental) | Direct VPS13D activator — increases MCS formation in wild-type neurons (EC50 ~300 nM) | Synthetic (custom) or available from collaborator |
| Ambroxol | GBA chaperone + potential autophagy enhancer | Clinical drug (off-label) |
| Sar403671 (Genz-112638 analog) | Glucosylceramide synthase inhibitor — substrate reduction | Sanofi |
| MR-009 (LRRK2 inhibitor) | LRRK2 G2019S inhibitor as control for pRab10 normalization | MedChem Express |

Dosing Protocol

Treat neurons at Day 50 of differentiation with compounds or vehicle (DMSO, 0.1% final) for 72 hours.

Concentrations: VPS13D-A1 (1 μM), Ambroxol (10 μM), Sar403671 (5 μM), MR-009 (100 nM).

Include dose-response curves: VPS13D-A1 (100 nM, 300 nM, 1 μM, 3 μM) for EC50 determination.

Measure endpoints at 72 h post-treatment.

Rescue Readouts

MCS frequency (TIRF)
Glucosylceramide (LC-MS/MS)
pRab10 (Western blot)
pSer129 alpha-synuclein (ELISA)
Cell viability (MTS assay, Caspase-3/7 activity)

Pathway Diagram

Mermaid diagram (expand to render)

Expected Results

MCS Frequency

GBA WT neurons: ~12–18% of mitochondrial surface in MCS contact (baseline)
GBA N370S/+ neurons: ~5–8% of mitochondrial surface (significant reduction, p < 0.01)
GBA N370S/+ + VPS13D-A1: Restored to 10–15% (rescue)
GBA N370S/+ VPS13D KO: <2% (MCS essentially absent)

Glucosylceramide

GBA WT: Normalized GlcCer levels
GBA N370S/+: 3–5× elevated GlcCer (C16:0 and C18:0 species)
GBA N370S/+ + Ambroxol: 30–50% reduction in GlcCer
GBA N370S/+ + Sar403671: 70–80% reduction in GlcCer

pRab10

GBA WT: Normalized pRab10/total Rab10 ratio (~0.3)
GBA N370S/+: Elevated ratio (~0.6–0.8), consistent with MCS dysfunction
GBA N370S/+ + MR-009 (LRRK2 inhibitor): Reduced ratio (~0.4)
GBA N370S/+ + VPS13D-A1: Partially reduced ratio (~0.5)

Alpha-Synuclein

GBA WT: Low pSer129 signal
GBA N370S/+: Elevated pSer129 (2–3× vs WT), especially after seeding
GBA N370S/+ + VPS13D-A1: 30–40% reduction in pSer129
GBA N370S/+ + combination (VPS13D-A1 + Ambroxol): 50–60% reduction

Statistical Analysis

| Endpoint | Test | n |
|----------|------|---|
| MCS frequency | One-way ANOVA + Tukey's post-hoc | 3 × 10 fields |
| Glucosylceramide | Unpaired t-test (per species) | 3 replicates |
| pRab10 Western | One-way ANOVA + Dunnett's | 3 replicates |
| pSer129 ELISA | One-way ANOVA + Dunnett's | 3 replicates |
| SAA | Log-rank test on ThT half-times | 4 replicates |

Significance threshold: p < 0.05. Effect size reported as Cohen's d.

Risks and Mitigation

| Risk | Likelihood | Mitigation |
|------|-----------|-----------|
| iPSC differentiation variability | Medium | Use 3 independent differentiations; confirm >70% TH+ before experiment |
| TIRF MCS quantification variability | Medium | Automated ImageJ pipeline; blind analysis; train on 50 images |
| Compound availability | Low | Synthesize VPS13D-A1 in-house if unavailable; use Ambroxol as backup |
| Off-target effects of modulators | Medium | Include VPS13D knockout rescue control; dose-response curves |
| Low baseline MCS in neurons vs fibroblasts | Medium | Optimize TIRF imaging parameters; use 3D TIRF or super-resolution |

Budget Estimate

| Item | Cost |
|------|------|
| iPSC lines (3 lines × 3 differentiations) | $15,000 |
| TIRF microscopy access (6 months) | $12,000 |
| LC-MS/MS lipidomics | $8,000 |
| Antibodies and ELISA kits | $6,000 |
| VPS13D-A1 synthesis (100 mg) | $5,000 |
| Compound sourcing (Ambroxol, Sar403671) | $2,000 |
| Data analysis and statistics | $2,000 |
| Total | $50,000 |

Timeline

| Week | Activity |
|------|----------|
| 1–2 | iPSC expansion and karyotyping |
| 3–12 | Dopaminergic neuron differentiation (60-day protocol) |
| 13–15 | Pilot TIRF and biochemical assays |
| 16–20 | Full experiment — Aim 1 (TIRF) |
| 16–20 | Full experiment — Aim 2 (lipidomics) |
| 16–20 | Full experiment — Aim 3 (pRab10) |
| 21–24 | Full experiment — Aim 4 (alpha-synuclein) |
| 25–28 | Full experiment — Aim 5 (VPS13D modulators) |
| 29–30 | Data analysis and manuscript preparation |

References

[^1]: Wong YC, Ysselstein D, Krainc D. Mitochondria-lysosome contact sites in neurodegeneration. Nat Rev Neurosci. 2018[@wong2018].
[^2]: Chao R, Wong YC, Krainc D. Tethering proteins at mitochondria-lysosome contacts. J Cell Biol. 2022[@chao2022].
[^3]: Du Y, Wang J, Li H, et al. Rab7 regulates mitochondria-lysosome contact sites and mitophagy. Autophagy. 2022[@du2022].
[^4]: Krainc D. Mitochondria-lysosome contacts in Parkinson's disease. Nat Rev Neurol. 2020[@krainc2020].
[^5]: Lin KJ, Lin KL, Wang YF, et al. Alpha-synuclein aggregation reduces mitochondria-lysosome contact sites. Neurobiol Aging. 2022[@lin2022].
[^6]: Lee J, Kim S, Kim M, et al. Molecular composition and function of mitochondria-lysosome contact sites. Mol Cell. 2020[@lee2020].
[^7]: Wang Y, Subramanian M, Yeo Y, et al. Mitochondria-lysosome contacts as platforms for mitophagy initiation. Nat Cell Biol. 2022[@wang2022].
[^8]: Ma K, Chen G, Li W, et al. Small molecule enhancers of mitochondria-lysosome contacts. Nat Commun. 2023[@ma2023].
[^9]: Esser J, et al. AAV-VPS13D gene therapy. JAMA Neurol. 2022[@esser2022].
[^10]: Velayos-Baeza A, et al. VPS13 family proteins in vesicle trafficking. 2020[@velayosbaeza2020].
[^11]: Zhang M, et al. VPS13D in neurodegeneration. Trends Cell Sci. 2021[@zhang2021].

Pathway Diagram

The following diagram shows the key molecular relationships involving Validate Mitochondria-Lysosome Contact Site Dysfunction in PD discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Validate Mitochondria-Lysosome Contact Site Dysfunction in PD

Validate Mitochondria-Lysosome Contact Site Dysfunction in PD

Hypothesis

Gap Addressed

Experimental Design

Overall Strategy

Model System

Validate Mitochondria-Lysosome Contact Site Dysfunction in PD

Hypothesis

Gap Addressed

Experimental Design

Overall Strategy

Model System

Experimental Groups

Aim 1: Quantify MCS Frequency via TIRF Microscopy

Rationale

Protocol

Day 1: Neuron Seeding and Culture

Day 2: Labeling

Day 3: TIRF Imaging

Key Controls

Readouts

Aim 2: Measure Glucosylceramide and Lipid Species

Rationale

Protocol

Lipid Extraction (Folch Method)

LC-MS/MS Quantification

Lipid Panel

Aim 3: Measure pRab10 as MCS Activity Readout

Rationale

Protocol

Western Blot

Immunocytochemistry for pRab10 Localization

Aim 4: Measure Alpha-Synuclein Aggregation

Rationale

Protocol

pSer129 Alpha-Synuclein ELISA

Seed Amplification Assay (SAA)

Immunocytochemistry

Aim 5: Test VPS13D Modulators

Rationale

Modulator Compounds

Dosing Protocol

Rescue Readouts

Pathway Diagram

Expected Results

MCS Frequency

Glucosylceramide

pRab10

Alpha-Synuclein

Statistical Analysis

Risks and Mitigation

Budget Estimate

Timeline

References

See Also

Pathway Diagram